Affect,COVID-19 vaccines,risk perception,trust,vaccination refusal,worry

Schizophrenia is frequently accompanied with social cognitive disturbances. Cannabis represents one established environmental factor associated with the onset and progression of schizophrenia. The present cross-sectional study aimed to investigate the association of facial emotion recognition (FER) performance with cannabis use in 2039 patients with schizophrenia, 2141 siblings, and 2049 healthy controls (HC). FER performance was measured using the Degraded Facial Affect Recognition Task (DFAR). Better FER performance as indicated by higher DFAR-total scores was associated with lifetime regular cannabis use in schizophrenia (B = 1.36, 95% CI 0.02 to 2.69), siblings (B = 2.17, 95% CI 0.79 to 3.56), and HC (B = 3.10, 95% CI 1.14 to 5.06). No associations were found between DFAR-total and current cannabis use. Patients with schizophrenia who started to use cannabis after the age of 16 showed better FER performance than patients who started earlier (B = 2.50, 95% CI 0.15 to 4.84) and non-users (B = 3.72, 95 CI 1.96 to 5.49). Better FER performance was found also in siblings who started to use cannabis after 16 compared to non-users (B = 2.37, 95% CI 0.58 to 4.16), while HC using cannabis performed better than non-users at DFAR-total regardless of the age at onset. Our findings suggest that lifetime regular cannabis use may be associated with better FER regardless of the psychosis risk, but that FER might be moderated by age at first use in people with higher genetic risk. Longitudinal studies may clarify whether there is a cause-and-effect relationship between cannabis use and FER performance in psychotic and non-psychotic samples. (C) 2022 The Author(s). Published by Elsevier B.V.

Readmission is a poor outcome associated with significant economic and psychosocial burden, particularly among young people. This study aimed to investigate predictors of time to readmission, the number of readmissions, and the cumulative duration of all readmissions among adolescent psychiatric inpatients over a 20-year observation period. A total of 508 adolescents participated in the original study. The length of index hospitalisation, previous inpatient admissions, the number of psychiatric diagnoses, and the severity of depression, anxiety, mania, psychosis, obsessive-compulsive disorder, eating disorder, conduct disorder, and alcohol and substance use were used to predict readmissions. Separate Bayesian regressions were conducted to examine the impact of these predictors on time to readmission, number of readmissions and the cumulative duration of readmissions. The severity of psychosis symptoms predicted all three outcomes. Once participants with existing schizophrenia spectrum diagnoses were removed from the sample, psychosis symptoms still predicted time to readmission and the number of readmissions. Previous inpatient admissions predicted more frequent admissions during the observation period. The severity of depression symptoms was associated with shorter time to first readmission. Looking at a range of patient and service level measures, psychosis symptoms predicted all three readmission outcomes in psychiatric inpatients. This finding suggests that psychosis symptoms may be a useful transdiagnostic marker of illness severity, predicting poor outcome into adulthood.